ClariVest Asset Management’s Amneal Pharmaceuticals AMRX Stock Holding History

ClariVest Asset Management’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$8.36K	Hold	1,317	–	–	﹤0.01%	424
2024 Q2	$8.36K	Buy	1,317 +449	+52%	+$2.85K	﹤0.01%	424
2024 Q1	$5.26K	Buy	868 +135	+18%	+$761	﹤0.01%	455
2023 Q4	$4.45K	Buy	733 +160	+28%	+$713	﹤0.01%	465
2023 Q3	$3K	Buy	573 +187	+48%	+$697	﹤0.01%	463
2023 Q2	$1K	Hold	386	–	–	﹤0.01%	576
2023 Q1	$1K	Sell	386 -97,424	-100%	-$194K	﹤0.01%	609
2022 Q4	$195K	Sell	97,810 -160	-0.2%	-$359	0.01%	420
2022 Q3	$198K	Sell	97,970 -266	-0.3%	-$745	0.01%	421
2022 Q2	$312K	Sell	98,236 -49,282	-33%	-$179K	0.01%	428
2022 Q1	$616K	Buy	147,518 +34,079	+30%	+$151K	0.02%	349
2021 Q4	$543K	Sell	113,439 -3,816	-3%	-$19K	0.02%	422
2021 Q3	$626K	Sell	117,255 -2,927	-2%	-$14.7K	0.02%	404
2021 Q2	$614K	Buy	120,182 +162	+0.1%	+$921	0.02%	397
2021 Q1	$808K	Buy	120,020 +118,862	+10,264%	+$659K	0.03%	318
2020 Q4	$5K	Hold	1,158	–	–	﹤0.01%	582
2020 Q3	$4K	Hold	1,158	–	–	﹤0.01%	565
2020 Q2	$6K	Buy	+1,158	New	+$4.77K	﹤0.01%	606

Other funds holding AMRX

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClariVest Asset Management's AMRX Position: Q3 2024 in Review

ClariVest Asset Management held its Amneal Pharmaceuticals (AMRX) position steady in Q3 2024 at 1,317 shares worth $8.36K. The position accounts for ﹤0.01% of the portfolio, ranked #424.

ClariVest Asset Management first reported a position in AMRX in Q2 2020 and has held it in 18 quarters since. The position peaked at $808K in Q1 2021. 183 funds tracked by Wall St. Rank hold AMRX as of Q3 2024.

ClariVest Asset Management held 1,317 shares of Amneal Pharmaceuticals worth $8.36K as of Q3 2024.
ClariVest Asset Management left its Amneal Pharmaceuticals share count unchanged in Q3 2024.
Amneal Pharmaceuticals made up ﹤0.01% of ClariVest Asset Management's portfolio in Q3 2024, its #424 holding.
ClariVest Asset Management first reported a position in Amneal Pharmaceuticals in Q2 2020 and has held it in 18 quarters since.
ClariVest Asset Management's Amneal Pharmaceuticals position peaked at $808K in Q1 2021.
183 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2024.

Based on ClariVest Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.